Improving HER2 testing reproducibility in HER2-low breast cancer

Abstract

HER2 is a pillar biomarker in breast cancer, and it is assessed by immunohistochemistry (IHC) using a three-tier scoring system and reflex in situ hybridization (ISH) for IHC score 2+. Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression, i.e. IHC score 1+ or ISH-negative IHC score 2+. Both primary and acquired resistance to anti-HER2 therapies remains a challenge in the treatment of breast cancers according to the HER2 positivity continuum. Thus, the ability to precisely discriminate among HER2-zero, HER2-low, and HER2-positive breast cancers is no longer a mere academic exercise. HER2 testing criteria, guidelines, and quality controls are re-gaining momentum for this new clinical need. Therefore, all preanalytical and analytical variables that might trouble the sensitivity and reproducibility of this test should be carefully considered to address all possible issues and open all possible therapeutic opportunities for breast cancer patients.

Keywords

Breast cancer / biomarkers, HER2, HER2 low, targeted therapy, antibody-drug conjugates, immunohistochemistry, ISH

References

[1] Venetis K,Sajjadi E.HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer.Front Mol Biosci2022;9:834651 PMCID:PMC8965450

[2] Wolff AC,Hicks DG.American Society of Clinical OncologyCollege of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Arch Pathol Lab Med2014;138:241-56 PMCID:PMC4086638

[3] Wolff AC,Allison KH.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update.J Clin Oncol2018;36:2105-22

[4] Pondé N,El-Hachem G,Piccart M.Treatment of advanced HER2-positive breast cancer: 2018 and beyond.Cancer Treat Rev2018;67:10-20

[5] Modi S,Yamashita T.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med2022;387:9-20

[6] Hamilton E,Shiller SM.Targeting HER2 heterogeneity in breast cancer.Cancer Treat Rev2021;100:102286

[7] Wolff AC,Schwartz JN.American Society of Clinical OncologyCollege of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol2007;25:118-45

[8] Vance GH,Bloom KJ.College of American PathologistsGenetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.Arch Pathol Lab Med2009;133:611-2

[9] Ahn S,Lee K.HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med2020;54:34-44 PMCID:PMC6986968

[10] Wolff AC,Hicks DG.American Society of Clinical OncologyCollege of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol2013;31:3997-4013

[11] Gajaria PK,Pai T,Desai SB.Dual-color dual-hapten in situ hybridization (D-DISH) - comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.Indian J Pathol Microbiol2020;63:194-9

[12] Sandén E,Tryggvadottir H.Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.Virchows Arch2020;477:317-20 PMCID:PMC7371653

[13] Marchiò C,Marques A,Berrino E.Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond.Semin Cancer Biol2021;72:123-35

[14] Ercolani C,Di Benedetto A.Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.J Exp Clin Cancer Res2017;36:143 PMCID:PMC5640946

[15] Picornell AC,Alvarez E.Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.BMC Genomics2019;20:452 PMCID:PMC6547580

[16] Najjar S.Updates on breast biomarkers.Virchows Arch2022;480:163-76

[17] Dai WF,Nagamuthu C.Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer.JAMA Oncol2022;8:597-606 PMCID:PMC8874900

[18] Viale G.Pathology after neoadjuvant treatment - how to assess residual disease.Breast2022;62 Suppl 1:S25-8 PMCID:PMC9097800

[19] Exman P.HER2-positive metastatic breast cancer: a comprehensive review.Clin Adv Hematol Oncol2021;19:40-50

[20] Vernieri C,Brambilla M.Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives.Crit Rev Oncol Hematol2019;139:53-66

[21] Zhang Y.The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.Pharmacol Ther2021;218:107677 PMCID:PMC7855784

[22] Venetis K,Sajjadi E,Fusco N.Cellular immunotherapy in breast cancer: the quest for consistent biomarkers.Cancer Treat Rev2020;90:102089

[23] Corti C,Sajjadi E,Curigliano G.CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.Expert Opin Investig Drugs2022;31:593-605

[24] Hou Y,Wei L.HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.Breast Cancer Res Treat2017;166:447-57

[25] Chandarlapaty S,Giri D.Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.Clin Cancer Res2012;18:6784-91 PMCID:PMC3525734

[26] Goel S,Watt AC.Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors.Cancer Cell2016;29:255-69 PMCID:PMC4794996

[27] Fusco N,Fassan M.PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer.Front Oncol2021;11:644737 PMCID:PMC8027489

[28] Trowe T,Calkins K.EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Clin Cancer Res2008;14:2465-75

[29] Rexer BN,Narasanna A.Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.Clin Cancer Res2013;19:5390-401 PMCID:PMC3809918

[30] Indini A,Grossi F.Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors.Int J Mol Sci2021;22:4774 PMCID:PMC8125530

[31] Diamantis N.Antibody-drug conjugates-an emerging class of cancer treatment.Br J Cancer2016;114:362-7

[32] Keam SJ.Trastuzumab Deruxtecan: first approval.Drugs2020;80:501-8

[33] Modi S,Murthy RK.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study.J Clin Oncol2020;38:1887-96 PMCID:PMC7280051

[34] deruxtecan is effective in HER2-low breast cancer.Cancer Discov2020;10:488

[35] Tarantino P,Tayob N.Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.JAMA Oncol2022;8:1177-83

[36] Fernandez AI,Bellizzi A.Examination of low ERBB2 protein expression in breast cancer tissue.JAMA Oncol2022;8:1-4 PMCID:PMC8814969

[37] Eiger D,Saúde-Conde R.The exciting new field of HER2-low breast cancer treatment.Cancers (Basel)2021;13:1015 PMCID:PMC7957750

[38] Banerji U,Saura C.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol2019;20:1124-35

[39] Iwata H,Doi T.Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts.JCO2018;36:2501-2501

[40] Schettini F,Brasó-Maristany F.Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.NPJ Breast Cancer2021;7:1 PMCID:PMC7782714

[41] Tarantino P,Tolaney SM.HER2-low breast cancer: pathological and clinical landscape.J Clin Oncol2020;38:1951-62

[42] Denkert C,Schneeweiss A.Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.Lancet Oncol2021;22:1151-61

[43] Fusco N,Sajjadi E.Assessment of estrogen receptor low positive status in breast cancer: implications for pathologists and oncologists.Histol Histopathol2021;36:1235-45

[44] Zhang H,Ajabnoor RM,Hicks DG.Applying the new guidelines of HER2 testing in breast cancer.Curr Oncol Rep2020;22:51

[45] Sapino A,Recupero D.Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues.Front Oncol2013;3:129 PMCID:PMC3659312

[46] Zhang H,Turner BM.HER2-low breast cancers.Am J Clin Pathol2022;157:328-36

[47] Schrohl AS,Jensen SS,Brünner N.Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.Histopathology2011;59:975-83 PMCID:PMC3263426

[48] Bianchi S,Paglierani M.Tuscany Breast Cancer Study GroupAccuracy and reproducibility of HER2 status in breast cancer using immunohistochemistry: a quality control study in tuscany evaluating the impact of updated 2013 ASCO/CAP recommendations.Pathol Oncol Res2015;21:477-85

[49] Jensen SG,Christensen IJ,Hansen A.Evaluation of analytical accuracy of HER2 status in patients with breast cancer: comparison of HER2 GPA with HER2 IHC and HER2 FISH.APMIS2020;128:573-82

[50] Tarantino P,Parsons HA.Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review.JAMA Oncol2022;8:629-35

[51] Angerilli V,Pagni F,Malapelle U.The role of the pathologist in the next-generation era of tumor molecular characterization.Diagnostics (Basel)2021;11:339 PMCID:PMC7922586

[52] Ivkovic-Kapic T,Moldvaji E et al.Interlaboratory concordance in HER2 testing: results of a Serbian ring-study.J buon2019;24:1045-53